Soticlestat

N/A

Report date: 2023/12/06 14:03:25
NME

Base Information

Drug NameSoticlestat
Drug Alias NameOV-935TAK-935
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCholesterol 24-hydroxylase inhibitors
TargetsCholesterol 24-hydroxylase
Therapy Area/IndicationsDup15q syndromeCDKL5 deficiency disorderNeurodevelopmental Disorders +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[24] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTakeda (China) International Trading Co LtdBushu Pharmaceuticals Ltd. Kawagoe FactoryTakeda Pharmaceutical Co Ltd +[5] 
Inactive CompaniesOvid Therapeutics IncMillennium Pharmaceuticals Inc
Active IndicationsSeizuresLennox Gastaut SyndromeEpilepsies, Myoclonic +[5] 
Inactive IndicationsDup15q syndromeCDKL5 deficiency disorderNeurodevelopmental Disorders +[6] 

Other Information

ATC CodeN/A
Related LinksKEGG